Suppression of nocturnal, palatable and glucoprivic intake in rats by the kappa opioid antagonist, nor-binaltorphamine

Brain Res. 1990 Nov 26;534(1-2):313-6. doi: 10.1016/0006-8993(90)90147-4.

Abstract

The increased food intake in the rat during the first two hours of the dark cycle was significantly inhibited by central pretreatment with either the selective kappa opioid antagonist, nor-binaltorphamine (NorBNI, 20 micrograms, i.c.v., 53-54%) or naltrexone (NTX, 20 micrograms, i.c.v., 47-60%). Short-term (2 h) intake of a high-fat diet was significantly inhibited by central NorBNI (1-20 micrograms, 33-79%) and NTX (20 micrograms, 47-51%). Hyperphagia induced by the anti-metabolic glucose analogue, 2-deoxy-D-glucose was significantly inhibited by central NorBNI (20 micrograms, 40-68%) and NTX (20 micrograms, 28-69%). These data suggest that the kappa receptor subtype, in addition to other opioid receptor subtypes, influence these forms of feeding behavior.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Brain / drug effects
  • Brain / physiology*
  • Circadian Rhythm
  • Dose-Response Relationship, Drug
  • Feeding Behavior / drug effects*
  • Male
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Receptors, Opioid / drug effects*
  • Receptors, Opioid / physiology
  • Receptors, Opioid, kappa
  • Reference Values

Substances

  • Receptors, Opioid
  • Receptors, Opioid, kappa
  • norbinaltorphimine
  • Naltrexone